Asthma Drugs Market in the US 2015-2019 is a new market research publication announced by Reportstack. Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.
The analysts forecast that the asthma drugs market in the US to grow at a CAGR of 4.64% over the period 2014-2019.
To access full report with TOC, please visit Asthma Drugs Market in the US 2015-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:
• Bronchodilators
• Leukotriene antagonists
• Mast cell stabilizers
• Immunosuppressants
• Combination of LABA/ICS
The report, Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
Other prominent vendors
This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:
• Bronchodilators
• Leukotriene antagonists
• Mast cell stabilizers
• Immunosuppressants
• Combination of LABA/ICS
The report, Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
Other prominent vendors
• Addex Therapeutics
• Alkermes
• AstraZeneca
• Aurobindo Pharma
• Avanir Pharmaceuticals
• Cerecor
• Chugai Pharmaceutical
• Dart NeuroScience
• Dr. Reddy's Laboratories
• Edgemont Pharmaceuticals
• E-Therapeutics
• Euthymics
• Evotec
• F. Hoffmann-La Roche
• Fabre Kramer
• Gedeon Richter
• H. Lundbeck
• Intra-Cellular Therapies
• Janssen Pharmaceuticals
• Lupin
• Luye Pharma
• MSI Methylation Sciences
• Naurex
• Neuralstem
• Novartis
• Opko Health
• Otsuka Pharmaceutical
• Pierre Fabre
• Shire
• SK Biopharmaceuticals
• Somerset Pharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals
• Suven
• Takeda Pharmaceutical
• Teva Pharmaceutical
• Torrent Pharmaceuticals
• Valeant Pharmaceuticals
Market driver
• Rise in disease prevalence
• For a full, detailed list, view our report
Market challenge
• Unknown disease etiology
• For a full, detailed list, view our report
Market trend
• Popularity of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Companies Mentioned
AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment